Healthcare provider profile · identity verified

Nelson A Mata, MD

Internal Medicine · SAN JUAN, TX · NPI 1518931377

Profile state: partd only Open Payments: 2025 Medicare Part D: 2024 Last identity check: 2026-08-10 Page data build: 2026-08-12

Verified facts

What the public records show

We did not find matching Open Payments records for this doctor in 2025.

These records do not establish that a payment influenced prescribing or medical care.

Payment overview · 2025

General Payments

We did not find matching Open Payments records for this doctor in the selected program year.

Separate record types

Research & Ownership

Research Payments (direct recipient): not present in the loaded data

Associated Research Funding (for example, named PI): not present in the loaded data

Ownership / Investment: not present in the loaded data

These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.

Analysis 1 · Payment-linked products

Products named in Open Payments records

No payment-linked product analysis is available because no matching General Payment records were found for the selected year.

Public prescribing for products named in payments

There is no explicit payment-product set available for a Part D comparison.

The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.

Analysis 2 · Same-company prescribing overlap

Drugs reported in other payments from the same company that also appear in Medicare Part D

This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.

There is no payer-company set available for this comparison.

These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.

Public Medicare Part D data

Provider-and-drug rows loaded for 2024

Brand	Generic	Claims	Beneficiaries
Atorvastatin Calcium	Atorvastatin Calcium	666	208
Levothyroxine Sodium	Levothyroxine Sodium	282	86
Metoprolol Succinate	Metoprolol Succinate	232	66
Omeprazole	Omeprazole	225	80
Lisinopril	Lisinopril	203	57
Metformin Hcl	Metformin Hcl	185	59
Farxiga	Dapagliflozin Propanediol	176	46
Amlodipine Besylate	Amlodipine Besylate	165	53
Rosuvastatin Calcium	Rosuvastatin Calcium	138	46
Tamsulosin Hcl	Tamsulosin Hcl	134	47
Levocetirizine Dihydrochloride	Levocetirizine Dihydrochloride	117	45
Jardiance	Empagliflozin	116	33
Ozempic	Semaglutide	115	17
Gabapentin	Gabapentin	114	40
Donepezil Hcl	Donepezil Hcl	112	36
Pantoprazole Sodium	Pantoprazole Sodium	112	37
Losartan Potassium	Losartan Potassium	96	34
Tradjenta	Linagliptin	96	28
Escitalopram Oxalate	Escitalopram Oxalate	95	29
Glimepiride	Glimepiride	93	26
Sertraline Hcl	Sertraline Hcl	92	33
Fluticasone Propionate	Fluticasone Propionate	84	40
Alendronate Sodium	Alendronate Sodium	81	25
Clopidogrel	Clopidogrel Bisulfate	77	28
Meloxicam	Meloxicam	77	30
Furosemide	Furosemide	72	31
Hydrochlorothiazide	Hydrochlorothiazide	71	22
Alprazolam	Alprazolam	67	13
Ibuprofen	Ibuprofen	67	43
Glipizide-Metformin	Glipizide/Metformin Hcl	65	19
Simvastatin	Simvastatin	63	18
Olmesartan Medoxomil	Olmesartan Medoxomil	60	16
Pravastatin Sodium	Pravastatin Sodium	60	17
Hydrocodone-Acetaminophen	Hydrocodone/Acetaminophen	54	suppressed
Lisinopril-Hydrochlorothiazide	Lisinopril/Hydrochlorothiazide	53	17
Nifedipine Er	Nifedipine	50	15
Paroxetine Hcl	Paroxetine Hcl	50	17
Lantus Solostar	Insulin Glargine,hum.Rec.Anlog	49	17
Folic Acid	Folic Acid	47	18
Cefdinir	Cefdinir	44	40
Finasteride	Finasteride	44	14
Albuterol Sulfate Hfa	Albuterol Sulfate	43	13
Hydralazine Hcl	Hydralazine Hcl	42	16
Meclizine Hcl	Meclizine Hcl	38	18
Olmesartan-Hydrochlorothiazide	Olmesartan/Hydrochlorothiazide	37	13
Carvedilol	Carvedilol	36	11
Tramadol Hcl	Tramadol Hcl	34	15
Valsartan	Valsartan	34	13
Clonazepam	Clonazepam	32	suppressed
Ramipril	Ramipril	32	suppressed
Trazodone Hcl	Trazodone Hcl	32	12
Isosorbide Mononitrate Er	Isosorbide Mononitrate	31	12
Xarelto	Rivaroxaban	31	suppressed
Allopurinol	Allopurinol	30	suppressed
Duloxetine Hcl	Duloxetine Hcl	30	suppressed
Azithromycin	Azithromycin	29	26
Bupropion Xl	Bupropion Hcl	29	suppressed
Celecoxib	Celecoxib	26	suppressed
Losartan-Hydrochlorothiazide	Losartan/Hydrochlorothiazide	26	11
Memantine Hcl Er	Memantine Hcl	26	suppressed
Spironolactone	Spironolactone	25	suppressed
Zolpidem Tartrate	Zolpidem Tartrate	25	suppressed
Ezetimibe	Ezetimibe	24	suppressed
Fenofibrate	Fenofibrate Nanocrystallized	24	suppressed
Montelukast Sodium	Montelukast Sodium	24	suppressed
Esomeprazole Magnesium	Esomeprazole Magnesium	22	suppressed
Pioglitazone Hcl	Pioglitazone Hcl	22	suppressed
Ulticare Pen Needle	Pen Needle, Diabetic	22	suppressed
Valsartan-Hydrochlorothiazide	Valsartan/Hydrochlorothiazide	22	suppressed
Eliquis	Apixaban	21	11
Tresiba Flextouch U-100	Insulin Degludec	21	suppressed
Levofloxacin	Levofloxacin	20	17
Potassium Chloride	Potassium Chloride	20	suppressed
Single Use Swab	Alcohol Antiseptic Pads	20	suppressed
Famotidine	Famotidine	19	suppressed
Fluconazole	Fluconazole	19	18
Ipratropium-Albuterol	Ipratropium/Albuterol Sulfate	19	suppressed
Janumet	Sitagliptin Phos/Metformin Hcl	19	suppressed
Vitamin D2	Ergocalciferol (Vitamin D2)	19	suppressed
Amlodipine Besylate-Benazepril	Amlodipine Besylate/Benazepril	18	suppressed
Ciprofloxacin Hcl	Ciprofloxacin Hcl	18	18
Metoprolol Tartrate	Metoprolol Tartrate	18	suppressed
Fenofibrate	Fenofibrate	17	suppressed
Paxlovid	Nirmatrelvir/Ritonavir	17	16
Pregabalin	Pregabalin	17	suppressed
Clonidine Hcl	Clonidine Hcl	16	suppressed
Amoxicillin-Clavulanate Potass	Amoxicillin/Potassium Clav	15	13
Mupirocin	Mupirocin	15	14
Risperidone	Risperidone	15	suppressed
Ropinirole Hcl	Ropinirole Hcl	15	suppressed
Toujeo Solostar	Insulin Glargine,hum.Rec.Anlog	15	suppressed
Cephalexin	Cephalexin	14	13
Humalog Mix 75-25 Kwikpen	Insulin Lispro Protamin/Lispro	14	suppressed
Hydrocortisone	Hydrocortisone	14	12
Hydroxychloroquine Sulfate	Hydroxychloroquine Sulfate	14	suppressed
Naproxen	Naproxen	14	suppressed
Januvia	Sitagliptin Phosphate	13	suppressed
Levetiracetam	Levetiracetam	13	suppressed
Mounjaro	Tirzepatide	13	suppressed
Nadolol	Nadolol	13	suppressed
Quetiapine Fumarate	Quetiapine Fumarate	13	suppressed
Rybelsus	Semaglutide	13	suppressed
Telmisartan	Telmisartan	13	suppressed
Citalopram Hbr	Citalopram Hydrobromide	12	suppressed
Irbesartan	Irbesartan	12	suppressed
Myrbetriq	Mirabegron	12	suppressed
Nano 2nd Gen Pen Needle	Pen Needle, Diabetic	12	suppressed
Ssd	Silver Sulfadiazine	12	suppressed
Amiodarone Hcl	Amiodarone Hcl	11	suppressed
Brimonidine Tartrate-Timolol	Brimonidine Tartrate/Timolol	11	suppressed
Diltiazem 24hr Er (Cd)	Diltiazem Hcl	11	suppressed
Silver Sulfadiazine	Silver Sulfadiazine	11	suppressed

Timeline

Payment and prescribing data by year

Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.

Year	General Payments	Main payer	Explicit products	Company overlaps	Part D coverage
2025	—	—	—	—	—
2024	—	—	—	—	Complete

Questions to ask

Questions you could discuss with your doctor

Are there reasonable alternatives I should understand when we discuss treatment options?
How should I interpret the industry-payment records shown here in the context of my care?

These are general questions generated from reviewed templates. They are not personalized medical advice.

Sources and limitations

How to read this page

Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.

Loaded source releases

Dataset	Year	Publication	Source
CMS Open Payments — General Payments	2025	2026-06-30	Original source
Medicare Part D Prescribers by Provider and Drug	2024	2026-05-06	Original source
NPPES Data Dissemination V2	current / reference data	2026-08-10	Original source

Methodology version: 2.1

Editorial template version: 2.4

Product contract version: 2.0

Schema version: 0.7.0

Page data build: 2026-08-12T23:34:59.370714+00:00

Publication policy: eligible for indexing after public-launch controls are enabled

Full methodology · Questions & answers · Report a possible error